Marina Tintelnot-Blomley

This inventor holds 18 USPTO granted patents and 10 published patent applications and 1 EPO patent. Top assignee: Novartis Ag. Active years: 2009-2020.

USPTO Granted Patents = 18 (Patent Applications = 10)

% Patents Active = 61.1

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 6.6

ph-index = 5

Forward Citations = 137(Granted Patents)

Company Filing History:

18 out of 3,975

Novartis Ag

patents

Years Active: 2009-2020

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10683287 - Heterocyclic derivatives and their use in the treatment of neurological disorders (2020-06-16),

2. 10442808 - Pyrazolo pyrimidine derivatives and their use as MALT1 inhbitors (2019-10-15),

3. 10301296 - Heterocyclic derivatives and their use in the treatment of neurological disorders (2019-05-28),

4. 10035794 - Heterocyclic derivatives and their use in the treatment of neurological disorders (2018-07-31),

5. 9815842 - Pyrazolo pyrimidine derivatives and their use as MALT1 inhibitors (2017-11-14),

6. 9670193 - Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease (2017-06-06),

7. 9550758 - Heterocyclic derivatives and their use in the treatment of neurological disorders (2017-01-24),

8. 9284284 - Oxazine derivatives and their use in the treatment of disease (2016-03-15),

9. 9056843 - Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease (2015-06-16),

10. 8865712 - Heterocyclic derivatives and their use in the treatment of neurological disorders (2014-10-21),

11. 8637508 - Heterocyclic derivatives and their use in the treatment of neurological disorders (2014-01-28),

12. 8207164 - Oxazine derivatives and their use in the treatment of neurological disorders (2012-06-26),

13. 8093406 - Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors (2012-01-10),

14. 8039455 - Macrocyclic compounds useful as BACE inhibitors (2011-10-18),

15. 8008250 - Macrocyclic compounds and compositions useful as BACE inhibitors (2011-08-30),

Title: Marina Tintelnot-Blomley: Pioneering Innovation for a Sustainable Future

Introduction:

Marina Tintelnot-Blomley, an esteemed inventor based in Maulburg, DE, is celebrated for her unwavering commitment to innovation and sustainability. With a total of 18 patents to her name, she has solidified her position as a visionary inventor whose work continues to inspire others in the field.

Latest Patents:

Tintelnot-Blomley's most recent patents showcase her dedication to advancing healthcare and medical research. Her groundbreaking inventions include novel heterocyclic compounds for the treatment of neurological disorders, particularly Alzheimer's Disease and diabetes. Additionally, she has introduced new pyrazolo-pyrimidine derivatives that act as MALT1 inhibitors, opening new possibilities for medicinal interventions.

Career Highlights:

Throughout her illustrious career, Tintelnot-Blomley has consistently pushed the boundaries of innovation. Her expertise in developing pharmaceutical compositions and medicaments has garnered recognition within the industry. As a key figure at Novartis AG, she has contributed significantly to the advancement of cutting-edge medical solutions.

Collaborations:

Tintelnot-Blomley is known for her collaborative spirit, having worked closely with esteemed colleagues such as Rainer Machauer and Siem Jacob Veenstra. Their synergistic efforts have led to the creation of revolutionary inventions that have the potential to shape the future of medicine.

Conclusion:

Marina Tintelnot-Blomley's pioneering spirit and dedication to sustainability underscore her status as a trailblazing inventor. Her remarkable contributions to the field of healthcare and pharmaceuticals serve as a testament to her innovative prowess and unwavering commitment to creating a better tomorrow.